In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche gets rights to SmithKline's Kytril

Executive Summary

Upon final completion of its merger with Glaxo Wellcome, SmithKline Beecham will sell its anti-emitic drug Kytril (granisetron hydrochloride), indicated for chemotherapy, radiotherapy, and postoperative nausea and vomiting, to Roche for $1.23bn in cash.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register